Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab and Atezolizumab IV FDC in PD-L1-selected Solid Tumors
NCT05661578Phase 2Completed
- Sponsor
- Roche
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in solid tumor, sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events. Started May 2023; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05661578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661578.